Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
WARNER CHILCOTT LABORATORIES IRELAND LIMITED et al v. IMPAX LABORATORIES, INC. et al
Case Number:
2:08-cv-06304
Court:
Nature of Suit:
Judge:
Firms
- Chiesa Shahinian
- Curtis Mallet-Prevost
- Florek & Endres
- Hill Wallack
- Lite DePalma
- McCarter & English
- Patunas Law
- Rivkin Radler
- Saiber LLC
- Saul Ewing
- Stevens & Lee
- White & Case
Companies
Sectors & Industries:
-
September 05, 2013
Warner To Pay Mylan $12M In Damages After Doryx IP Row
Warner Chilcott PLC and Mayne Pharma International Pty. Ltd. have agreed to pay $12 million to Mylan Inc. and Mylan Pharmaceuticals Inc. to resolve Mylan's damages claim following patent litigation over Warner's acne drug Doryx, according to a regulatory notice filed Wednesday.
-
April 30, 2012
Judge OKs Mylan's Acne Generic But Keeps Patent Intact
A New Jersey federal judge on Monday held that two generic anti-acne drugs made by Mylan Pharmaceuticals Inc. and Impax Laboratories Inc. do not infringe a patent for Warner Chilcott Co. LLC's brand-name drug Doryx, but refused to find a Doryx patent invalid.
-
January 16, 2009
Warner Chilcott Brings New Patent Suit Over Doryx
Warner Chilcott Ltd. and Mayne Pharma International Pty. Ltd. have filed a patent infringement lawsuit seeking to prevent Sandoz Inc. from marketing a generic version of the antibiotic Doryx less than a month after targeting three other drugmakers in a similar suit.